Multiple Sclerosis Relapsing-remitting
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis Relapsing-remitting.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-30EMA Authorised: Mayzent (siponimod fumaric acid) — Novartis Europharm Limited
Mayzent (siponimod fumaric acid) has been authorised in the EU for relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2026-07-28Clinical Trial Results: Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis [Phase 4]
Phase 4 clinical trial evaluating the impact of cladribine tablets on central nervous system biomarkers in multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2026-07-20Clinical Trial Results: Effects of Chiropractic Care on Cytokine Levels in Multiple Sclerosis [NA]
Clinical trial results evaluating the effects of chiropractic care on cytokine levels in relapsing-remitting multiple sclerosis.
-
EMA approval · 2026-07-01EMA Authorised: Teriflunomide Viatris (previously Teriflunomide Mylan) (teriflunomide) — Viatris Limited
Teriflunomide Viatris has been authorised for relapsing-remitting multiple sclerosis in the EU.
-
EMA approval · 2026-06-12EMA Authorised: Fingolimod Mylan (Fingolimod) — Mylan Pharmaceuticals Limited
Fingolimod Mylan has been authorised for multiple sclerosis, relapsing-remitting, by the EMA.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-02-24EMA Authorised: Teriflunomide Accord (teriflunomide) — Accord Healthcare S.L.U.
The EMA authorised Teriflunomide Accord (teriflunomide) for relapsing-remitting multiple sclerosis. This represents approval of a generic te…
-
EMA approval · 2025-11-24EMA Authorised: Mayzent (siponimod fumaric acid) — Novartis Europharm Limited
The EMA authorised Mayzent (siponimod) for relapsing-remitting multiple sclerosis in the EU, with Novartis Europharm Limited as the marketin…
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data
A Canadian observational study examining patient persistence with Ofatumumab in relapsing-remitting multiple sclerosis using patient support…
-
CLINICAL_TRIALS research · 2024-12-18Clinical Trial Update: A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments
A completed clinical trial examined participants' perspectives beyond clinical efficacy of monoclonal antibody–based treatments for relapsin…
-
CLINICAL_TRIALS trial_result · 2024-03-08Clinical Trial Update: IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study [Phase 1, Phase 2]
Clinical trial update for IMCY-0141 in multiple sclerosis (relapsing-remitting) spanning Phase 1 and Phase 2 with safety and efficacy endpoi…
-
CLINICAL_TRIALS trial_result · 2024-03-07Clinical Trial Update: Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis [Phase 3]
Phase 3 trial assessing EGb 761® versus placebo for cognitive impairment in adults with relapsing-remitting multiple sclerosis; study comple…
-
EMA withdrawal · 2023-12-22EMA Revoked: Dimethyl fumarate Teva (dimethyl fumarate) — Teva GmbH
EMA revoked the marketing authorization for Teva's dimethyl fumarate product.
-
EMA withdrawal · 2023-12-22EMA Revoked: Dimethyl fumarate Neuraxpharm (dimethyl fumarate) — Laboratorios Lesvi S.L.
The EMA has revoked the Dimethyl fumarate product from Laboratorios Lesvi S.L. for relapsing-remitting multiple sclerosis.
-
EMA withdrawal · 2023-12-22EMA Revoked: Dimethyl fumarate Polpharma (dimethyl fumarate) — Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
EMA revoked the Dimethyl fumarate Polpharma product, a therapy for relapsing-remitting multiple sclerosis, indicating withdrawal of authoriz…
-
EMA withdrawal · 2023-12-22EMA Revoked: Dimethyl fumarate Mylan (dimethyl fumarate) — Mylan Ireland Limited
EMA revoked the marketing authorization for dimethyl fumarate (Mylan Ireland Limited) intended for multiple sclerosis (relapsing-remitting).
-
CLINICAL_TRIALS trial_result · 2023-05-16Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants [Phase 3]
Phase 3 pediatric trial evaluating Dimethyl Fumarate and Peginterferon Beta-1a for relapsing-remitting multiple sclerosis was terminated.
-
EMA withdrawal · 2022-11-03EMA Application withdrawn: Dimherity (dimethyl fumarate) — Sandoz GmbH
The EMA withdrew the application for Dimherity (dimethyl fumarate) by Sandoz GmbH for multiple sclerosis relapsing-remitting.
-
CLINICAL_TRIALS trial_result · 2022-04-28Clinical Trial Update: B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis [Phase 4]
Phase 4 trial comparing B cell-tailored ocrelizumab to standard ocrelizumab in relapsing-remitting multiple sclerosis; current status is unk…
-
CLINICAL_TRIALS research · 2022-04-22Clinical Trial Update: Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis [Phase 4]
A Phase 4 clinical trial update investigates the effects of hydroxyvitamin D3 on multiple sclerosis and related conditions.
-
CLINICAL_TRIALS research · 2021-10-26Clinical Trial Update: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential [Phase 4]
Phase 4 trial update exploring mechanisms of action and neuroprotective potential of alemtuzumab in relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2021-10-12Clinical Trial Update: RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. [Phase 3]
Phase 3 trial comparing Rituximab versus Fumarate in newly diagnosed relapsing-remitting multiple sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2021-09-08Clinical Trial Update: Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis [Phase 2, Phase 3]
Phase 2/3 trial comparing BCD-054 with Avonex for relapsing-remitting multiple sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2021-07-22Clinical Trial Update: A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab [Phase 4]
A Phase 4 pilot study evaluating the biological effects of a planned 12-week interruption of natalizumab in patients with relapsing forms of…
-
CLINICAL_TRIALS trial_result · 2021-06-03Clinical Trial Update: Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS) [Phase 4]
Phase 4 trial update for Acthar Gel in relapsing-remitting multiple sclerosis; study terminated with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-04-19Clinical Trial Update: RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS [Phase 3]
Phase 3 clinical trial update for rituximab long-term dose in relapsing-remitting multiple sclerosis (RIDOSE-MS).